1. Search Result
Search Result
Isoforms Recommended: DYRK2
Results for "

DYRK2

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

1

Recombinant Proteins

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-147066

    DYRK Cancer
    Dyrk1A-IN-4 (compound 48) is a potent and orally active DYRK1A and DYRK2 inhibitor with IC50s of 2 nM and 6 nM, respectively. Dyrk1A-IN-4 has anticancer effects .
    Dyrk1A-IN-4
  • HY-110320

    Haspin Kinase DYRK Cancer
    LDN-209929 dihydrochloride is a potent and selective haspin kinase inhibitor (IC50=55 nM) with180-fold selectivity verses DYRK2 (IC50=9.9 μM). LDN-209929 is a optimized analogue of LDN-192960 (HY-13455) [2].
    LDN-209929 dihydrochloride
  • HY-161598

    Ligands for Target Protein for PROTAC Cancer
    DYRK2 ligand 1 is a target protein ligand of PROTAC DYRK2 degrader 1 (HY-161597). DYRK2 ligand 1 can be used to study cancer .
    DYRK2 ligand 1
  • HY-RS04098

    Small Interfering RNA (siRNA) Others

    DYRK2 Human Pre-designed siRNA Set A contains three designed siRNAs for DYRK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    DYRK2 Human Pre-designed siRNA Set A
    DYRK2 Human Pre-designed siRNA Set A
  • HY-RS04099

    Small Interfering RNA (siRNA) Others

    Dyrk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Dyrk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Dyrk2 Mouse Pre-designed siRNA Set A
    Dyrk2 Mouse Pre-designed siRNA Set A
  • HY-RS04100

    Small Interfering RNA (siRNA) Others

    Dyrk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Dyrk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Dyrk2 Rat Pre-designed siRNA Set A
    Dyrk2 Rat Pre-designed siRNA Set A
  • HY-161014

    DYRK Cancer
    DYRK2-IN-1 (Compd 54) is an orally bioavailable DYRK2 inhibitor, with an IC50 of 14 nM. DYRK2-IN-1 (Compd 54) can be used in the study of prostate cancer .
    DYRK2-IN-1
  • HY-161597

    PROTACs Cancer
    PROTAC DYRK2 degrader 1 (compound CP134) is a PROTAC degrader of DYRK2 (Red: DYRK2 inhibitor(HY-161598), black: linker (HY-42776), Blue: E3 ligase ligand (HY-10984)) .
    PROTAC DYRK2 degrader 1
  • HY-153949

    DYRK Cancer
    YK-2-69 is a highly selective DYRK2 inhibitor with an IC50 value of 9 nM. YK-2-69 specifically interacts with Lys-231 and Lys-234 of DYRK2 and can be utilized in researches related to prostate cancer .
    YK-2-69
  • HY-135002

    Haspin Kinase Cancer
    LDN-209929 is a potent haspin kinase inhibitor, with IC50 values of 55 nM and 9.9 μM for Haspin and DYRK2, respectively .
    LDN-209929
  • HY-13455
    LDN-192960
    2 Publications Verification

    Haspin Kinase DYRK Cancer
    LDN-192960 is an inhibitor of Haspin and Dual-specificity Tyrosine-regulated Kinase 2 (DYRK2) with IC50s of 10 nM and 48 nM, respectively .
    LDN-192960
  • HY-13455A
    LDN-192960 hydrochloride
    2 Publications Verification

    Haspin Kinase DYRK Cancer
    LDN-192960 hydrochloride is an inhibitor of Haspin and Dual-specificity Tyrosine-regulated Kinase 2 (DYRK2) with IC50s of 10 nM and 48 nM, respectively .
    LDN-192960 hydrochloride
  • HY-105309
    GSK-626616
    3 Publications Verification

    DYRK Cardiovascular Disease
    GSK-626616 is a potent, orally bioavailable inhibitor of DYRK3 (IC50=0.7 nM). GSK-626616 inhibits other members of the DYRK family (e.g., DYRK1A and DYRK2) with similar potency, which is a potential therapy for the treatment of anemia .
    GSK-626616
  • HY-111379

    DYRK CDK GSK-3 Neurological Disease Metabolic Disease Cancer
    EHT 5372 is a highly potent and selective inhibitor of DYRK's family kinases with IC50s of 0.22, 0.28, 10.8, 93.2, 22.8, 88.8, 59.0, 7.44, and 221 nM for DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK4, GSK-3α, and GSK-3β, respectively [2].
    EHT 5372
  • HY-155723

    CDK DYRK Others
    Leucettinib-92 (compound 92) is an inhibitor of DYRK/CLK kinase, The IC50s are 147 nM (CLK1), 39 nM (CLK2), 5.2 nM (CLK4), 0.8 μM (CLK3), 124 nM (DYRK1A), 204 nM (DYRK1B), 0.16 μM (DYRK2), respectively. 1.0 μM (DYRK3), 0.52 μM (DYRK4), 2.78 μM (GSK3) .
    Leucettinib-92
  • HY-156816

    Casein Kinase DYRK Cancer
    ON 108600 is a inhibitor for CK2 (Casein Kinase2)/TNIK/DYRK1 , with the IC50s for DYRK1A/DYRKB, DYRK2, CK2α1/CK2α2, and TNIK of 0.016 μm/0.007 μM, 0.028 μM, 0.05 μM/0.005 μM, and 0.005 μM, respectively. ON 108600 has antitumor activity .
    ON 108600
  • HY-117049

    CDK DYRK Neurological Disease
    Leucettine L41 is a potent inhibitor of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), DYRK2, CDC-like kinase 1 (CLK1), and CLK3 (IC50s = 0.04, 0.035, 0.015, and 4.5 µM, respectively) . Leucettine L41 prevents lipid peroxidation and the accumulation of reactive oxygen species (ROS) induced by Aβ25-35 in the hippocampus in a mouse model of Alzheimer’s disease-like toxicity. Leucettine L41 also prevents memory deficits induced by Aβ25-35 in the same model [2].
    Leucettine L41
  • HY-112296
    T025
    2 Publications Verification

    CDK Apoptosis DYRK Cancer
    T025 is an orally active and highly potent inhibitor of Cdc2-like kinase (CLKs), with Kd values of 4.8, 0.096, 6.5, 0.61, 0.074, 1.5 and 32 nM for CLK1, CLK2, CLK3, CLK4, DYRK1A, DYRK1B and DYRK2, respectively. T025 induces caspase-3/7-mediated cell apoptosis. T025 reduces CLK-dependent phosphorylation. T025 exerts anti-proliferative activities in both hematological and solid cancer cell lines (IC50 values: 30-300 nM). T025 has an anti-tumor efficiency, mainly for MYC-driven disease research .
    T025

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: